<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0004031" disease_type="Disease or Syndrome" abbrv="">Pulmonary aspergillosis</z:e> following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment </plain></SENT>
<SENT sid="1" pm="."><plain>We treated a patient who had acquired <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> some 80 days after allogeneic bone marrow transplantation, with oral <z:chebi fb="0" ids="6076">itraconazole</z:chebi>, 600 mg daily </plain></SENT>
<SENT sid="2" pm="."><plain>After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="6076">Itraconazole</z:chebi> should be considered for therapy of <z:e sem="disease" ids="C0004031" disease_type="Disease or Syndrome" abbrv="">pulmonary aspergillosis</z:e> in this and other immunocompromised settings </plain></SENT>
</text></document>